CN107848991B - (z)-4-(5-((3-苄基-4-氧代-2-硫代噻唑烷-5-亚基)甲基)呋喃-2-基)苯甲酸的固体形式 - Google Patents

(z)-4-(5-((3-苄基-4-氧代-2-硫代噻唑烷-5-亚基)甲基)呋喃-2-基)苯甲酸的固体形式 Download PDF

Info

Publication number
CN107848991B
CN107848991B CN201680041800.5A CN201680041800A CN107848991B CN 107848991 B CN107848991 B CN 107848991B CN 201680041800 A CN201680041800 A CN 201680041800A CN 107848991 B CN107848991 B CN 107848991B
Authority
CN
China
Prior art keywords
salt
xrpd
pattern
powder diffraction
ray powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680041800.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN107848991A (zh
Inventor
A·J·巴伯沙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GB006 Inc
Original Assignee
GB006 Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GB006 Inc filed Critical GB006 Inc
Publication of CN107848991A publication Critical patent/CN107848991A/zh
Application granted granted Critical
Publication of CN107848991B publication Critical patent/CN107848991B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/08—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with only one hydroxy group and one amino group bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/10—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/40—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton with quaternised nitrogen atoms bound to carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201680041800.5A 2015-06-12 2016-06-10 (z)-4-(5-((3-苄基-4-氧代-2-硫代噻唑烷-5-亚基)甲基)呋喃-2-基)苯甲酸的固体形式 Active CN107848991B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562175066P 2015-06-12 2015-06-12
US62/175,066 2015-06-12
US201662275655P 2016-01-06 2016-01-06
US62/275,655 2016-01-06
PCT/US2016/037067 WO2016201356A1 (en) 2015-06-12 2016-06-10 Solid forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid

Publications (2)

Publication Number Publication Date
CN107848991A CN107848991A (zh) 2018-03-27
CN107848991B true CN107848991B (zh) 2022-01-14

Family

ID=57504544

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680041800.5A Active CN107848991B (zh) 2015-06-12 2016-06-10 (z)-4-(5-((3-苄基-4-氧代-2-硫代噻唑烷-5-亚基)甲基)呋喃-2-基)苯甲酸的固体形式

Country Status (12)

Country Link
US (4) US10723726B2 (https=)
EP (1) EP3307722B1 (https=)
JP (1) JP2018521121A (https=)
KR (1) KR102663856B1 (https=)
CN (1) CN107848991B (https=)
AU (2) AU2016275125A1 (https=)
BR (2) BR112017026406A2 (https=)
CA (2) CA3221219A1 (https=)
ES (1) ES2896674T3 (https=)
IL (1) IL256237B (https=)
SG (1) SG10201911442XA (https=)
WO (1) WO2016201356A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016275125A1 (en) 2015-06-12 2018-01-25 Gb006, Inc. Solid forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid
WO2018126072A1 (en) * 2016-12-29 2018-07-05 Adhaere Pharmaceuticals, Inc. Heterocyclic integrin agonists
MX394899B (es) * 2017-03-30 2025-03-24 Merck Patent Gmbh Forma solida de (s)-[2-cloro-4-fluoro-5-(7-morfolin-4-il-quinazolin-4-il)fenil]-(6-metoxi-piridazin-3-il)-metanol.
TWI687415B (zh) 2017-08-17 2020-03-11 美商基利科學股份有限公司 Hiv蛋白質膜抑制劑之固體形式
CN120053445A (zh) 2018-07-16 2025-05-30 吉利德科学公司 用于治疗hiv的衣壳抑制剂
CN113166056B (zh) 2018-11-28 2024-07-05 罗欣药业(上海)有限公司 一种雌激素受体下调剂的盐型、晶型及其制备方法
WO2020236668A1 (en) 2019-05-17 2020-11-26 Gb006, Inc. Leukadherin-1 alone or in combination for use in the treatment of cancer
WO2021061665A1 (en) * 2019-09-23 2021-04-01 Gb006, Inc. Integrin agonist prodrugs
WO2021096988A1 (en) 2019-11-12 2021-05-20 Gb006, Inc. Crystalline salt forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid
WO2023039170A1 (en) * 2021-09-09 2023-03-16 Musc Foundation For Research Development Selective targeting of cd38 activity as an immunostimulatory and antitumor strategy
US20260062432A1 (en) * 2022-09-02 2026-03-05 Rexpharmtech Co., Ltd Novel benfotiamine choline salt
WO2024081449A1 (en) * 2022-10-14 2024-04-18 Rush University Medical Center Cd11b agonists for treatment of autoimmune disease
CN121197154A (zh) * 2025-11-13 2025-12-26 首都医科大学附属北京天坛医院 Mac-1激动剂在制备治疗和/或缓解脑出血药物中的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101083989A (zh) * 2004-12-23 2007-12-05 欧洲细胞治疗责任有限公司 噻唑烷酮衍生物作为抗血管生成剂的用途
WO2008005651A2 (en) * 2006-06-08 2008-01-10 Decode Chemistry, Inc. Cyclic carboxylic acid rhodanine derivatives for the treatment and prevention of tuberculosis
US7718680B2 (en) * 2004-09-23 2010-05-18 Burnham Institute For Medical Research Inhibition of lethal factor protease activity from anthrax toxin
CN103159695A (zh) * 2011-12-08 2013-06-19 首都师范大学 可抑制hiv复制并对耐药hiv病毒株有效的噻唑类化合物及其制备方法和用途
WO2013159082A1 (en) * 2012-04-20 2013-10-24 Adhaere Pharmaceuticals, Inc. Compounds and methods for regulating integrins

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040002526A1 (en) * 2002-04-03 2004-01-01 Cell Therapeutics, Inc. Phospholipase D inhibitors and uses thereof
EP1654380A4 (en) 2003-08-14 2009-09-09 Insight Biopharmaceuticals Ltd METHODS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATING HEPARANASE ACTIVATION AND USES THEREOF
TW200526638A (en) 2003-10-22 2005-08-16 Smithkline Beecham Corp 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline
FI20041129A0 (fi) 2004-08-30 2004-08-30 Ctt Cancer Targeting Tech Oy Tioksotiatsolidinoniyhdisteitä lääkkeinä käytettäviksi
WO2008082537A2 (en) 2006-12-19 2008-07-10 The General Hospital Corporation Compounds for modulating integrin cd11b/cd18
WO2008091532A1 (en) * 2007-01-19 2008-07-31 Panacos Pharmaceuticals, Inc. Salts of 3-o-(3',3'-dimethylsuccinyl)betulinic acid and solid state forms thereof
US9023876B2 (en) 2010-07-08 2015-05-05 Adhaere Pharmaceuticals, Inc. Compounds and methods for regulating integrins
AU2016275125A1 (en) 2015-06-12 2018-01-25 Gb006, Inc. Solid forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7718680B2 (en) * 2004-09-23 2010-05-18 Burnham Institute For Medical Research Inhibition of lethal factor protease activity from anthrax toxin
CN101083989A (zh) * 2004-12-23 2007-12-05 欧洲细胞治疗责任有限公司 噻唑烷酮衍生物作为抗血管生成剂的用途
WO2008005651A2 (en) * 2006-06-08 2008-01-10 Decode Chemistry, Inc. Cyclic carboxylic acid rhodanine derivatives for the treatment and prevention of tuberculosis
CN103159695A (zh) * 2011-12-08 2013-06-19 首都师范大学 可抑制hiv复制并对耐药hiv病毒株有效的噻唑类化合物及其制备方法和用途
WO2013159082A1 (en) * 2012-04-20 2013-10-24 Adhaere Pharmaceuticals, Inc. Compounds and methods for regulating integrins

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
A small molecule β2 integrin agonist improves chronic kidney allograft survival by reducing leukocyte recruitment and accompanying vasculopathy;Samia Q.Khan等;《Frontiers in Medicine》;20141112;第1卷;第1-11页 *
Micron-Size Drug Particles: Common and Novel Micronization Techniques;Norbert Rasenack等;《PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY》;20041231;第9卷(第1期);第2页左栏第1段、右栏第2段 *
Pharmaceutical Salts;STEPHEN M. BERGE等;《Journal of Pharmaceutical Sciences》;19770131;第66卷(第1期);第2页table1 *

Also Published As

Publication number Publication date
JP2018521121A (ja) 2018-08-02
US11111239B2 (en) 2021-09-07
IL256237A (en) 2018-02-28
NZ738836A (en) 2024-03-22
EP3307722B1 (en) 2021-08-04
SG10201911442XA (en) 2020-02-27
BR122023025347A2 (pt) 2024-01-16
US20250353840A1 (en) 2025-11-20
ES2896674T3 (es) 2022-02-25
EP3307722A4 (en) 2018-12-05
CA2988584C (en) 2024-01-23
CA3221219A1 (en) 2016-12-15
KR20180016443A (ko) 2018-02-14
AU2020270457A1 (en) 2020-12-10
CN107848991A (zh) 2018-03-27
IL256237B (en) 2021-12-01
AU2016275125A1 (en) 2018-01-25
US10723726B2 (en) 2020-07-28
CA2988584A1 (en) 2016-12-15
US20180354938A1 (en) 2018-12-13
AU2020270457B2 (en) 2022-10-20
BR112017026406A2 (pt) 2019-04-02
US20230227443A1 (en) 2023-07-20
US20200317657A1 (en) 2020-10-08
US12227497B2 (en) 2025-02-18
WO2016201356A1 (en) 2016-12-15
KR102663856B1 (ko) 2024-05-07
EP3307722A1 (en) 2018-04-18

Similar Documents

Publication Publication Date Title
CN107848991B (zh) (z)-4-(5-((3-苄基-4-氧代-2-硫代噻唑烷-5-亚基)甲基)呋喃-2-基)苯甲酸的固体形式
JP6524152B2 (ja) 選択的ｃｄｋ４／６阻害剤の固体形態
CN116507620B (zh) Cdk4抑制剂的固体形式
JP6946194B2 (ja) キナーゼを調節する化合物の固体形態
US10316032B2 (en) Solid forms of a compound for modulating kinases
JP2021176819A (ja) キナゾリン化合物を有効成分とする医薬組成物
CN110831939A (zh) 作为erk1/2抑制剂的6-嘧啶-异吲哚衍生物
CN111093651A (zh) Ido抑制剂的无定形和结晶形式
RU2786994C2 (ru) Фармацевтическое соединение
WO2025229177A1 (en) Crystalline forms of an n-substituted indole derivative
WO2025132831A1 (en) N-heteroaryl derivatives and uses thereof for treating cancer
EA049146B1 (ru) Аморфные и кристаллические формы ido-ингибиторов
EA041037B1 (ru) Аморфные и кристаллические формы ido-ингибиторов

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20190718

Address after: American California

Applicant after: GB006 Co.

Address before: Illinois Instrunment

Applicant before: Adhaere Pharmaceuticals, Inc.

GR01 Patent grant
GR01 Patent grant